Oculus Innovative Sciences Announces a Multi-Year Licensing Agreement With Eloquest Healthcare for Microcyn-Based Wound Care Products

Oculus Innovative Sciences, Inc. OCLS, today announced a multi-year licensing agreement with Eloquest Healthcare, a wholly owned subsidiary of Ferndale Pharma Group, Inc., to market multiple Microcyn®-based products in the United States under the Eloquest Healthcare brand, including Oculus' negative-pressure wound therapy solution and prescription wound care line. Negative pressure wound therapy is a therapeutic technique used to promote healing in acute or chronic wounds. Tim O'Halla, vice president and chief operating officer, Eloquest Healthcare, Inc., said, "We have been most impressed with the success of the Microcyn technology in a variety of uses around the globe. We are excited about the expected impact of adding Microcyn to our U.S. portfolio and look forward to growing its presence in the wound care market with particular emphasis on its use in conjunction with negative-pressure wound therapies." According to the agreement, Eloquest Healthcare has been granted an exclusive U.S. license for Microcyn-based negative-pressure wound therapy solution, and will promote Microcyn-based wound care products under Eloquest Healthcare Brand to U.S. hospitals, ambulatory surgical and acute care centers. Eloquest Healthcare plans to begin marketing both product lines beginning in January 2012.